Table 1.
General and clinical characteristics of the study subjects respective of cohort
| Type of cohort | Discovery cohort (N = 26) | Validation cohort (N = 95) | ||||
|---|---|---|---|---|---|---|
| Patients’ characteristics | sALS patients (n = 16) | Controls (n = 10) | sALS patients (n = 48) | Healthy controls (n = 47) | Disease controls (n = 30) | |
| Age (mean ± SD) | 65.62 ± 9.11 | 49.30 ± 14.88 | 66.67 ± 10.52 | 67.08 ± 10.89 | 69.00 ± 5.91 | |
| Gender (n) | Male | 9 | 5 | 29 | 29 | 17 |
| Females | 7 | 5 | 19 | 18 | 13 | |
| Disease duration from onset to collection, months (mean ± SD) | 17.18 ± 9.29 | 20.04 ± 18.43 | ||||
| Initial symptoms (n) | Bulbar | 3 | 20 | |||
| Upper limb | 10 | 17 | ||||
| Lower limb | 3 | 11 | ||||
| ALSFRS-R (mean ± SD) | 36.06 ± 10.59 | 33.15 ± 11.72 | ||||
| Bulbar paralysis scores of ALSFRS-R (mean ± SD) | 9,75 ± 3.51 | 8.06 ± 4.04 | ||||
| Barthel Index (mean ± SD) | 72.19 ± 31.99 | 68.02 ± 34.23 | ||||
| Disease duration from onset to end point, months (mean ± SD) | 31.00 ± 13.66 | 28.58 ± 18.72 | ||||